ArticleHematology, transfusion and cell therapy2026
CD30 expression in diffuse large B-cell lymphoma and primary mediastinal lymphoma: frequency, association with prognostic factors, and impact on survival.
Article in Hematology, transfusion and cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCD30 expression has been studied as a prognostic and therapeutic biomarker in diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) and primary mediastinal B-cell lymphoma (PMBCL). This study evaluated the frequency of CD30 expression, its association with National Comprehensive Cancer Network International Prognostic Index and cell of origin and impact prognosis.
methodsThis retrospective cohort study included patients diagnosed with DLBCL or PMBCL between 2009 and 2016 at the Instituto do Câncer do Estado de São Paulo. Adult patients who received curative-intent treatment and had available histopathological material were included. CD30-positive cases were tested for Epstein-Barr virus by in situ hybridization: positive cases were excluded.
resultsA total of 301 patients were analyzed (279 DLBCL and 22 PMBCL). CD30 positivity was found in 19.6% of cases (19% in DLBCL and 27.3% in PMBCL). Among the CD30-positive cases, nodal biopsies were more frequent (62.7%) than extranodal (37.3%) (p = 0.03). No significant association was found between CD30 expression and the National Comprehensive Cancer Network International Prognostic Index or cell of origin (germinal center B-cell-like vs. non-germinal center B-cell-like). CD30 expression did not impact overall survival (p = 0.22) or progression-free survival (p = 0.42). In the DLBCL subgroup, CD30 expression also showed no significant effect on overall survival (p = 0.35) or progression-free survival (p = 0.70).
conclusionThis is the first Brazilian and Latin American study to assess CD30 expression in DLBCL and PMBCL. CD30 expression was observed in 19.6% of cases, more commonly in nodal biopsies, but showed no prognostic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.